|
|
| |
| 1.3.4 Medications |
| |
| The workgroup
discussed the MCT/MS/FINEP invitation letter that defines
criteria for public selection of proposals for supporting
technological cooperation between the productive sector
and scientific and/or technological institutions within
the scope of the technological and industrial chain
in the pharmaceuticals area. |
 |
|
| |
Context
Initially, the subject Medications
was not inserted into the workshop’s program, but
given the relevance and volume of the appeals brought, it
was considered opportune to discuss the institutional agreement
between the Ministry of Health and the Ministry of Science
and Technology, with the participation of the Sectorial
Fund for Health (Fundo Setorial de Saúde
– CT-SAÚDE) and the National Fund for Health
(Fundo Nacional de Saúde). The call for
bid resulted from a demand from Forums, the Industrial Policy
and companies, which allows a greater success in the application
of resources.
Therefore, the dynamics and objectives
of this workgroup are different from the others, once the
subject of discussion will be the MCT/MS/FINEP invitation
letter, which defines criteria for the public selection
of proposals for supporting technological cooperation between
the productive sector and scientific and/or technological
institutions within the scope of the technological and industrial
chain in the pharmaceuticals area. The relevant points of
discussion that resulted in the priority setting for the
area are presented as follows.
|
Need to
strengthen the HR (Human Resources) development, mostly
in the clinical and preclinical research areas. |
Inclusion of medications originated
from natural products – the phytomedications
–, since it is a priority area of the MS, with
policy approval for SUS. Main demands come from researches
at the end of the chain, for development of products,
and also researches with plant species enlisted in
the National Lists of Medicinal and Phytotherapeutical
Plants, which is to be concluded by the Ministry of Health. |
| Importance of participating in
the Competitiveness Forum of the Pharmaceutical Productive
Chain. |
The proposal of the call for
bid conforms with the purpose of the law of innovation. |
The theme is discussed in the
Sectorial Fund for Health and, from 2004 on, the public-private
partnership was praised in the calls for bid. There
is a rule that reserves 50 percent of resources for
projects resulting from public-private partnerships.
In 2006, the actions are aimed to the area of medications,
thus representing an efficient moment for partnership
of the Ministry of Science and Technology with the Ministry of Health.. |
Importance of clearly putting
in the call for bid the priorities of the Ministry of Health. in the
area of neglected and high-cost diseases. It was suggested
to use the text of the Bioproducts call for bid as
reference. |
Interest in supporting thematic
projects with transpositions of scales, thus being
necessary to define patent situations – not
only product patents, but process patents as well. |
| Eleven percent of health budget
is destined to medications and the situation may reach
a point intolerable in 2010 if it remains in such proportion. |
The average time of development
for medication surrounds 10 to 20 years. Therefore,
projects that should be prioritized are the ones at
the end of the chain such as development of innovations,
namely pre-clinical and technological trials and essays. |
| The importance of linking research
scholarships for HR capacity-building is highlighted
as a point of the call for bid with the objective of
strengthening HR in the technological development step
with incentive from institutions. |
Another point of consensus for
inclusion in the document was in relation to the participations
of the Pharmaceutical Assistance Department (Departamento
de Assistência Farmacêutica –
DAF) and the Science and Technology Department in
the merit and follow-up assessment of supported projects. |
The call for bid shall aim to
public-private partnership projects with the objective
of developing researches that reduce the country’s
dependence on medications and fostering innovations. |
The importance of valuing priority
diseases is underscored not only in the economic aspect,
but in the social aspect as well. |
|
Methodology
Considering this group’s specificities,
the proposed methodology was not used. The discussion dynamics
used the policy agreement and the consensus among strategic
players on the approval of proposal of the MCT/MS/FINEP
invitation letter. This document defines criteria for public
selection of proposals for supporting technological cooperation
between the productive sector and scientific and/or technological
institutions within the scope of the technological and industrial
chain in the pharmaceuticals area.
Results
By consensus, the following changes
were made to the document:
Subjects/Segments/Priority Lines
With this Invitation Letter, projects
aiming to innovations in the technological and industrial
chain of the pharmaceutical area will be supported, and
proposals that approach activities included in the final
phase of the innovation development chain will be prioritized,
which are namely pharmaceutical formulation, scale transposition,
preclinical trials, toxicological trials and essays.
Exceptionally, proposals that purport
to develop innovations in the technological and industrial
chain in the pharmaceutical area at all phases will be considered
in order to obtain innovative products when they are aimed
to these priority diseases: Cerebrovascular disease; Sexually
transmitted diseases/AIDS; Hepatitis; High blood pressure;
Hansen’s disease; American tegumentary leishmaniasis;
Visceral leishmaniasis; Schistosomiasis; Malaria; Tuberculosis;
Cancer; Chagas disease; Dengue fever.
|
| |
Workgroup
|
Adriana Diaféria
|
ABDI – Brazilian
Agency for Industrial Development (Agência Brasileira
de Desenvolvimento Industrial) |
| Allan Kardec de Lima |
CNPq/MCT - National Council for
Scientific and Technological Development |
| Ângelo Rodrigues |
DAF/SCTIE - Pharmaceutical
Assistance Department of the Secretariat of Science,
Technology and Strategic Inputs - Ministry of Health |
| Belmiro Salles |
CNPq - National Council for
Scientific and Technological Development - Ministry of Science and technology |
| Carcílio Franco |
Decit/SCTIE - Science and
Technology Department of the Secretariat of Science,
Technology and Strategic Inputs - Ministry of Health |
| Cláudia Cunha |
DAF/SCTIE - Pharmaceutical
Assistance Department of the Secretariat of Science,
Technology and Strategic Inputs - Ministry of Health |
| Eliane Cortês |
SAS - Secretariat of Health
Care Attention (Secretaria de Atenção
à Saúde do Ministério da Saúde)
- Ministry of Health |
| J. Lourenço Seixas |
Decit/SCTIE - Science and Technology Department of the Secretariat of Science, Technology and Strategic Inputs - Ministry of Health |
| José Luís |
SAS - Secretariat of Health Care Attention (Secretaria de Atenção à Saúde do Ministério da Saúde) - Ministry of Health |
| Laura Campos |
CNPq - National Council for
Scientific and Technological Development - Ministry of Science
and Technology |
| Luís A Barretos de Castro |
MCT – Ministry of Science
and Technology |
| Manoel Roberto da Cruz Santos |
DAF/SCTIE/MS - Pharmaceutical
Assistance Department of the Secretariat of Science,
Technology and Strategic Inputs of the Ministry of Health |
Maura Pacheco
|
Finep - Research and Projects
Financing |
| Moisés Goldbaum |
SCTIE - Secretariat of Science,
Technology and Strategic Inputs - Ministry of Health |
| Simone Paiva |
Finep - Research and Projects
Financing |
| Sofia Daher |
CNPq - National Council for
Scientific and Technological Development - Ministry of Science
and Technology |
|
| |
|
|
